Drug research

Ibezapolstat

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as ACX-362E

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile InfectionNCT07513285	ACXP	Phase 2	Recruiting	2027-09-29Estimated
ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile InfectionNCT04247542	ACXP	Phase 2	Completed	2023-10-03Actual

ACXPRecruitingPrimary completion: 2027-09-29 · Estimated

Trial details

ACXPCompletedPrimary completion: 2023-10-03 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.